In response to the recent publication “Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes” by Dadzie et al., it is important to clarify and highlight the positive and unequivocal research and operational contributions from the American experience towards the worldwide elimination of human onchocerciasis (river blindness). The strategies of twice or more rounds of mass drug administration (MDA) of ivermectin per year, as well as the use of OV-16 serology have allowed four American countries to be verified by World Health Organization to have eliminated transmission of Onchocerca volvulus, the etiological agent. These advances were also implemented in Sudan and Uganda; currently, both are the only African countries where ivermectin MDA was safely stopped in several transmission zones. Programmatic treatment and evaluation approaches, pioneered in the Americas, are the most efficient among the existing tools for elimination, and their broader use could catalyze the successful elimination of this disease in Africa.

中文翻译：

---

到 2025 年在非洲消灭盘尾丝虫病：需要有广阔的视野

为响应 Dadzie 等人最近发表的“到 2025 年在非洲消除盘尾丝虫病是否可行：基于从非洲控制计划中吸取的经验教训的观点”，重要的是要澄清和强调来自非洲的积极和明确的研究和业务贡献美国在全球消除人类盘尾丝虫病（河盲症）方面的经验。每年两次或更多轮伊维菌素大规模药物管理（MDA）的策略以及OV-16血清学的使用使四个美洲国家得到世界卫生组织的验证，已经消除了盘尾丝虫的传播。病原体。这些进展也在苏丹和乌干达实施；目前，两者都是在几个传播区安全停止伊维菌素 MDA 的唯一非洲国家。美洲首创的规划治疗和评估方法是现有消除工具中最有效的，其更广泛的应用可以促进非洲成功消除这种疾病。